The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Betahistine dihydrochloride 24 mg Tablets



Azure Pharmaceuticals LtdPA22871/017/003

Main Information

Trade NameBetahistine dihydrochloride 24 mg Tablets
Active SubstancesBetahistine dihydrochloride
Dosage FormTablet
Licence HolderAzure Pharmaceuticals Ltd
Licence NumberPA22871/017/003

Group Information

ATC CodeN07CA01 betahistine

Status

License statusAuthorised
Licence Issued21/01/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportPDF Version
« Back